Literature DB >> 18070150

T cell activation profiles in Kawasaki syndrome.

P A Brogan1, V Shah, L A Clarke, M J Dillon, N Klein.   

Abstract

Superantigens (SAgs) are potent stimulators of T cells bearing specific Vbeta T cell receptors (TCR) and may play a role in the pathogenesis of Kawasaki syndrome (KS), although despite 15 years of intense study this area remains controversial. Because SAgs can cause Vbeta restricted T cell activation in the absence of Vbeta skewing the aims of this study were to describe a flow cytometric protocol to study both CD4 and CD8 Vbeta repertoires, and CD69 expression across the CD4 and CD8 Vbeta repertoire in children with KS. Sixteen children with KS were studied. There was no significant increase in overall peripheral blood CD4 or CD8 T cell activation as determined by CD69 expression. However, Vbeta restricted CD4 and/or CD8 activation was observed in eight of 11 (72%) of the KS patients, a finding not observed in healthy controls. Thirteen of 16 (81%) of the KS patients had evidence of either Vbeta skewing (particularly CD4 Vbeta2 and Vbeta5.1) and/or Vbeta restricted activation. Three patients had Vbeta restricted activation in the absence of skewing. We suggest that these preliminary observations highlight the many layers of complexity when considering T cell activation in KS, which could explain some of the conflicting studies regarding peripheral blood T cell activation and Vbeta skewing. It is likely that in order to move forward with this debate a combination of detailed microbiological, immunological and molecular techniques applied to individual patients will be required ultimately to prove or refute the SAg hypothesis of KS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070150      PMCID: PMC2276940          DOI: 10.1111/j.1365-2249.2007.03567.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  Oligoclonal IgA response in the vascular wall in acute Kawasaki disease.

Authors:  A H Rowley; S T Shulman; B T Spike; C A Mask; S C Baker
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

2.  Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research.

Authors:  P A Brogan; A Bose; D Burgner; D Shingadia; R Tulloh; C Michie; N Klein; R Booy; M Levin; M J Dillon
Journal:  Arch Dis Child       Date:  2002-04       Impact factor: 3.791

3.  Characterization of a novel staphylococcal enterotoxin-like superantigen, a member of the group V subfamily of pyrogenic toxins.

Authors:  Paul M Orwin; Donald Y M Leung; Timothy J Tripp; Gregory A Bohach; Cathleen A Earhart; Douglas H Ohlendorf; Patrick M Schlievert
Journal:  Biochemistry       Date:  2002-11-26       Impact factor: 3.162

Review 4.  Kawasaki disease: etiology, pathogenesis, and treatment.

Authors:  Karyl S Barron
Journal:  Cleve Clin J Med       Date:  2002       Impact factor: 2.321

Review 5.  Kawasaki disease and toxic shock syndrome--at last the etiology is clear?

Authors:  Nigel Curtis
Journal:  Adv Exp Med Biol       Date:  2004       Impact factor: 2.622

6.  Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury.

Authors:  P A Brogan; V Shah; N Klein; M J Dillon
Journal:  Arthritis Rheum       Date:  2004-02

7.  Analysis of T-cell receptor V-beta 2 in peripheral blood lymphocytes as a diagnostic marker for Kawasaki disease.

Authors:  P Reichardt; I Lehmann; G Sierig; M Borte
Journal:  Infection       Date:  2002-12       Impact factor: 3.553

8.  T cell Vbeta repertoires in childhood vasculitides.

Authors:  P A Brogan; V Shah; A Bagga; N Klein; M J Dillon
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

9.  Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease.

Authors:  Donald Y M Leung; H Cody Meissner; Stanford T Shulman; Wilbert H Mason; Michael A Gerber; Mary P Glode; Barry L Myones; J Gary Wheeler; Robin Ruthazer; Patrick M Schlievert
Journal:  J Pediatr       Date:  2002-06       Impact factor: 4.406

10.  Evidence for a superantigen mediated process in Kawasaki disease.

Authors:  N Curtis; R Zheng; J R Lamb; M Levin
Journal:  Arch Dis Child       Date:  1995-04       Impact factor: 3.791

View more
  11 in total

Review 1.  [New pathogenetic aspects in primary systemic vasculitides].

Authors:  P Lamprecht
Journal:  Internist (Berl)       Date:  2009-03       Impact factor: 0.743

Review 2.  Kawasaki disease: insights into pathogenesis and approaches to treatment.

Authors:  Stanford T Shulman; Anne H Rowley
Journal:  Nat Rev Rheumatol       Date:  2015-04-28       Impact factor: 20.543

3.  Unique activation status of peripheral blood mononuclear cells at acute phase of Kawasaki disease.

Authors:  K Ikeda; K Yamaguchi; T Tanaka; Y Mizuno; A Hijikata; O Ohara; H Takada; K Kusuhara; T Hara
Journal:  Clin Exp Immunol       Date:  2009-12-15       Impact factor: 4.330

4.  Increased frequency of immunoglobulin (Ig)A-secreting cells following Toll-like receptor (TLR)-9 engagement in patients with Kawasaki disease.

Authors:  L Giordani; M G Quaranta; A Marchesi; E Straface; D Pietraforte; A Villani; W Malorni; D Del Principe; M Viora
Journal:  Clin Exp Immunol       Date:  2010-12-22       Impact factor: 4.330

Review 5.  Vasculitis in children and adolescents: clinical presentation, etiopathogenesis, and treatment.

Authors:  Kjell Tullus; Stephen D Marks
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

6.  The risk of hospitalization for respiratory tract infection (RTI) in children who are treated with high-dose IVIG in Kawasaki Disease: a nationwide population-based matched cohort study.

Authors:  Wei-Te Lei; Chien-Yu Lin; Yu-Hsuan Kao; Cheng-Hung Lee; Chao-Hsu Lin; Shyh-Dar Shyur; Kuender-Der Yang; Jian-Han Chen
Journal:  PeerJ       Date:  2018-03-22       Impact factor: 2.984

Review 7.  The role of infection in Kawasaki syndrome.

Authors:  Nicola Principi; Donato Rigante; Susanna Esposito
Journal:  J Infect       Date:  2013-04-18       Impact factor: 6.072

8.  Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report.

Authors:  Robert J Brogan; Despina Eleftheriou; James Gnanapragasam; Nigel J Klein; Paul A Brogan
Journal:  Pediatr Rheumatol Online J       Date:  2009-01-21       Impact factor: 3.054

Review 9.  Management of Kawasaki disease.

Authors:  D Eleftheriou; M Levin; D Shingadia; R Tulloh; N J Klein; P A Brogan
Journal:  Arch Dis Child       Date:  2013-10-25       Impact factor: 3.791

10.  T-Helper Cytokine Profiles in Patients with Kawasaki Disease.

Authors:  Sang Bum Lee; Young Hyun Kim; Myung Chul Hyun; Yeo Hyang Kim; Hee Sun Kim; Young Hwan Lee
Journal:  Korean Circ J       Date:  2015-11-25       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.